A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results Abstract #1179

Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3
Aim(s): To evaluate the safety and efficacy of axitinib in patients with advanced carcinoid tumors
Materials and methods: We performed a phase II trial of axitinib 5 mg BID in patients with advanced low to intermediate grade carcinoid tumors. Prior antiangiogenic therapy with a dedicated VEGF pathway inhibitor was not permitted. The primary endpoints were PFS and 1-year PFS rate
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Mauro Cives

To read results and conclusion, please login ...

Further abstracts you may be interested in

#299 Clinical and Immunohistochemical Evaluation of Medullary Thyroid Cancer (MTC) and C Cell Hyperplasia (CCH)
Introduction: MTC and CCH has a variable clinical presentation and prognosis and no data are available on the correlation between immunoistochemical (IIC) characterization and clinical behavior.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Prof Laura De Marinis
Authors: Lugli F, Fusco A, Bianchi A, Milardi D, ...
#2011 Expression and Clinical Significance of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Phospho-VEGFR3 in Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: The expression of vascular endothelial growth factor Receptor 3 (VEGFR3) and phospho-VEGFR3 (pVEGFR3) in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and their clinical significance are still unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Professor Jie Chen
Authors: Zhang Y, Chen L, Lin Y, Chen M, ...
#211 Phase II Study of Sunitinib Following Hepatic Transarterial Embolization for Metastatic Neuroendocrine Tumors
Introduction: Hepatic transarterial embolization is often recommended for patients with liver-predominant metastatic NETs. Antiangiogenic therapy following embolization may delay tumor revascularization.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
#214 Comparison of the AJCC and ENETS Staging Classifications for Neuroendocrine Tumors of the Pancreas
Introduction: The AJCC Cancer Staging Manual (7th edition, 2010) has introduced a novel TNM staging classification for pancreatic NETs. This classification has not yet been validated.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors: Strosberg J, Cheema A, Weber J, Kvols L, ...
#217 Risk of Metastatic Spread in Patients with Early-Stage, Surgically Resected Pancreatic Neuroendocrine Tumors
Introduction: The risk of metastatic spread among patients with early-stage surgically resected pancreatic neuroendocrine tumors has not been well-established.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors: Strosberg J, Cheema A, Weber J, Kvols L, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.